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SWEDEHEART Registry: Troponinemia is not 
Innocent and Demands Careful Workup  
Among 48,872 patients, a cardiac troponin (cTn) 
level >99th percentile was found in 9,800 (20.1%) 
patients. The prevalence of cardiovascular (CV) risk 
factors as well as CV and nonCV comorbidities 
increased across higher cTn strata. In total, 7,529 
(15.4%) patients had a major adverse event (MAE), 
defined as the composite of all-cause mortality, MI, 
readmission for heart failure, or stroke over a median 
of 4.9 years). MAE risk was associated with higher 
cTn strata (hazard ratio–HR for highest assay-specific 
cTn tertile: 2.59; HR 3.57 in patients without CV 
comorbidities, renal dysfunction, LV dysfunction, or 
significant coronary stenosis) (Eggers KM et al, J Am 
Coll Cardiol 2019;73: 1–9).  
 
French SCAD Study: the rs9349379 Allele of the 
PHACTR1/EDN1 Genetic Locus Lying on 
Chromosome 6q24 is the First Genetic Risk Locus for 
Spontaneous Coronary Artery Dissection (SCAD) 
The previously reported risk allele for fibromuscular 
dysplasia (FMD) (rs9349379-A) was associated with a 
higher risk of SCAD in all studies. In a meta-analysis of 
1,055 SCAD patients and 7,190 controls, the odds ratio 
(OR) was 1.67 per copy of rs9349379-A. In a subset of 491 
SCAD patients, the OR estimate was higher for the 
association with SCAD in patients without FMD (OR: 
1.89) than in SCAD cases with FMD (OR: 1.60). There 
was no effect of genotype on age at first event, pregnancy 
associated SCAD, or recurrence (Adlam D et al, J Am Coll 
Cardiol 2019;73:58-66).  
  
COMPASS-CABG Study: Compared With Aspirin or 
Rivaroxaban Alone, the Combination of Rivaroxaban 
and Aspirin Did Not Prevent Early Failure of CABGs 
but Reduced MACE, Consistent With Outcomes in the 
Overall COMPASS Trial 
Among 1,448 COMPASS trial patients randomized 4-
14 days after CABG surgery to receive the combination of 
rivaroxaban plus aspirin, rivaroxaban alone, or aspirin 
alone, the combination of rivaroxaban and aspirin and the 
regimen of rivaroxaban alone did not reduce the graft 
failure rates compared with aspirin alone (combination vs. 
aspirin: 9.1% vs 8% failed grafts; odds ratio - OR: 1.13; 
p=0.45; rivaroxaban alone vs aspirin: 7.8% vs 8% failed 
grafts; OR: 0.95; p=0.75). Compared with aspirin, the 
combination was associated with fewer MACE (2.4% vs. 
3.5%; hazard ratio-HR: 0.69; p=0.34), whereas 
rivaroxaban alone was not (3.3% vs 3.5%; HR: 0.99; 
p=0.98). There was no fatal bleeding or tamponade within 
30 days of randomization (Lamy A et al, J Am Coll Cardiol 
2019;73:121-30)  
 
PFO closure: Durable Efficacy Against Recurrent 
Ischemic Events for Over a Decade  
Among 201 consecutive patients (mean age: 47 ± 12 
years, 51% women) who underwent successful PFO 
closure due to a cryptogenic embolism (76% stroke, 32% 
TIA, 1% systemic embolism) with 3.3% residual shunt, 
over a median follow-up of 12 years (range 10-17 years), 
13 patients died (all from noncardiovascular causes), and 
nondisabling stroke and TIA occurred in 2 and 6 patients, 
respectively. A history of thrombophilia (15%) tended to 
associate with a higher rate of ischemic events at follow-
up (p=0.067). Bleeding events occurred in 13 patients and 
were major (intracranial bleeding) in 4 patients (all of them 
under aspirin therapy at the time of the event). A total of 
42 patients stopped the antithrombotic treatment at a 
median of 6 months, and none had any ischemic or 
bleeding episode after a mean of 10 ± 4 years following 
treatment cessation (Wintzer-Wehekind J et al, J Am Coll 
Cardiol 2019; 73:278-87).  
 
French TAVI Registry: Anticoagulation Decreases 
Valve Dysfunction but Increases Mortality 
Of 12,804 TAVI patients, 11,469 (aged 82.8±0.07 
years; logistic Euroscore 17.8±0.1%; mean follow-
up: 1.3 years) were alive at discharge with known 
antithrombotic treatment. Neither aspirin nor 
clopidogrel was independently associated with 
mortality. Male sex (adjusted hazard ratio - aHR: 
1.63; p< 0.001), history of atrial fibrillation (1/3 of 
patients, n=3,836) (aHR: 1.41; p< 0.001), and chronic 
renal failure (aHR: 1.37; p< 0.001) were the strongest 
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independent correlates of mortality. Anticoagulation 
at discharge (adjusted odds ratio - aOR: 0.54; 
p=0.005) and a nonfemoral approach (aOR: 0.53; 
p=0.049) were independently associated with lower 
rates of bioprosthetic valve dysfunction (BVD), 
whereas chronic renal failure (aOR: 1.46; p=0.034) 
and prosthesis size≤23mm (aOR: 3.43; p< 0.001) 
yielded higher risk of BVD (Overtchouk P et al, J Am 
Coll Cardiol 2019;73:13-21). 
 
Long-Term TAVI Valve Function Seems 
Excellent, With no Increase in Gradient or 
Regurgitation at a Median of 5.8 Years, up to 10 
Years, With Severe Structural Valve Degeneration 
(SVD) Occurring in<0.5% of Patients  
Among 241 patients (79.3 ± 7.5 years of age; 46% 
female; 149 patients (64%) treated with a self-expandable 
valve and 80 (34.7%) with a balloon-expandable valve), 
more patients had none/trivial aortic regurgitation (AR) 
(47.5% vs. 33%), and fewer had mild AR (42.5% vs. 57%) 
at follow-up (p = 0.02). There was 1 case (0.4%) of severe 
SVD (AR) 5.3 years after implantation. There were 21 
cases (8.7%) of moderate SVD (mean 6.1 years post-
implantation; range 4.9 to 8.6 years). Twelve of these 
(57%) were due to new AR and 9 (43%) to restenosis. 
(Blackman DJ et al, J Am Coll Cardiol 2019; 73:537-45).  
 
Global Feasibility Study of Trans-Apical Mitral Valve 
Replacement (TMVR) in First 100 Patients: TMVR 
(Tendyne, Abbott) Eliminated MR in Nearly All Cases 
/1-Year Mortality 26% Among Survivors / Improved 
Functional Status and Quality of Life  
In the cohort (mean age 75.4 ± 8.1 years; 69% men), 
there were no intraprocedural deaths, 1 instance of major 
apical bleeding, and no acute conversion to surgery or need 
for cardiopulmonary bypass. Technical success was 96%. 
The 30-day rates of mortality and stroke were 6% and 2%, 
respectively. The 1-year survival free of all-cause 
mortality was 72.4%, with 84.6% of deaths due to cardiac 
causes. Among survivors at 1 year, 88.5% were NYHA 
function class I/II, with improvement in 6-min walk 
distance (p < 0.0001) and quality-of-life (p = 0.011). 
(Sorajja P et al, J Am Coll Cardiol 2019; 73:1250-60). 
 
First-in-Human Percutaneous Transseptal Balloon-
Expandable Mitral Valve Placement in 10 Patients with 
Severe Mitral Regurgitation (MR) at High Surgical 
Risk: Feasible in All but 1 Case, and Safe at 30 Days  
The new valve was implanted in 9 of 10 (90%) patients 
with severe MR of various etiologies (4 degenerative, 4 
functional, 2 mixed). By transesophageal echo, MR was 
reduced to ≤ trivial in all patients, and mean transmitral 
gradient was 2.3±1.4 mmHg. A pericardial effusion 
occurred in 1 patient managed with pericardiocentesis, and 
the device was not implanted. Median hospital stay was 1.5 
days. At 30 days, there was no stroke, MI, rehospitaliza-
tion, LVOT obstruction, device migration, embolization, 
or conversion to mitral surgery. One patient had recurrent 
MR due to a paravalvular leak, treated with a closure 
device. All other treated patients had ≤1+ MR. No patients 
died (Webb JG et al, J Am Coll Cardiol 2019;73:1239-46).  
 
PARTNER 2: TAVI is Cost-Effective vs Surgical 
Aortic Valve Replacement (AVR) in Patients With 
Severe Aortic Stenosis at Intermediate Risk for the US 
Healthcare System by Providing Greater Quality-
Adjusted Life Expectancy and Lower Long-Term 
Costs than AVR if Long-Term Data Demonstrate 
Comparable Late Mortality With TAVI and AVR, 
A total of 2032 patients were randomized to receive 
TAVI using the SAPIEN XT valve (XT-TAVR) or surgery 
(AVR) in the PARTNER 2A trial, whereas the PARTNER 
S3i registry included an additional 1078 patients treated 
with TAVI using the SAPIEN 3 valve (S3-TAVR). 
Although procedural costs were ≈$20 000 higher with 
TAVI than AVR, total cost differences for the index 
hospitalization were $2888 higher with XT-TAVR 
(P=0.014) and $4155 lower with S3-TAVR (P<0.001) due 
to reductions in length of stay with TAVI. Follow-up costs 
were lower with XT-TAVR (Δ=−$9304; P<0.001) and S3-
TAVR (Δ=−$11 377; P<0.001) than with AVR (Baron SJ 
et al, Circulation 2019;139:877–888) 
 
PARTNER 3: Among Patients With Severe Aortic 
Stenosis Who Were at Low Surgical Risk, the Rate of 
the Composite of Death, Stroke, or Rehospitalization at 
1 Year Was Significantly Lower With TAVI With a 
Balloon-Expandable Valve Than With Surgery  
Among 1000 randomized patients (mean age 73 years, 
and mean STS risk score 1.9%), the Kaplan–Meier 
estimate of the rate of the primary composite end point at 
1 year was significantly lower in the TAVI group than in 
the surgery group (8.5% vs. 15.1%; absolute difference, 
−6.6 percentage points; P<0.001 for noninferiority; hazard 
ratio, 0.54; P=0.001 for superiority). At 30 days, TAVI 
resulted in a lower rate of stroke than surgery (P=0.02) and 
in lower rates of death or stroke (P=0.01) and new-onset 
atrial fibrillation (P<0.001). TAVI also resulted in a shorter 
index hospitalization than surgery (P<0.001) and in a 
lower risk of a poor treatment outcome at 30 days 
(P<0.001). There were no significant between-group 
differences in major vascular complications, new 
permanent pacemaker insertions, or moderate or severe 
paravalvular regurgitation (Mack MJ et al, New Engl J 
Med 2019 March 16; doi: 10.1056/NEJMoa1814052).  
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NOTION Trial: In Patients With Severe Aortic 
Stenosis at Low Surgical Risk, Rate of Structural 
Deterioration of Valves is Greater Within the First 6 
Years After Surgical AVR Than TAVI, While Rates of 
Valve Failure, Endocarditis, and All-Cause Mortality 
are Low and Similar With Both Methods 
Among all-comer patients with severe aortic 
stenosis and lower surgical risk for mortality 
randomized 1:1 to TAVI (n=139) or surgical AVR 
(n=135), at 6 years, the rates of all-cause mortality 
were similar for TAVI (42.5%) and surgical AVR 
(37.7%) patients (p=0.58). The rate of structural valve 
degeneration (SVD) was higher for surgical AVR 
than TAVI (24.0% vs. 4.8%; p< 0.001), whereas there 
were no differences in NonSVD (57.8% vs 54%; 
p=0.52) or endocarditis (5.9% vs 5.8%; p=0.95). 
Valve Failure rates were similar after surgical AVR 
and TAVI through 6 years (6.7% vs 7.5%; p=0.89) 
(Sondegaard L et al, J Am Coll Cardiol 2019;73:546-53).  
 
STS/ACC TVT Registry: Compared With the Year 
Before, Non-CV Hospitalizations Increase in the Year 
Following TAVI / Only Hospitalizations for Heart 
Failure (HF) Decrease  
Among 15,324 patients undergoing TAVI, (median 
age 84 years, the median STS score 7; 61.1% via 
transfemoral access), post-TAVI, HF hospitalization rates 
and hospitalized days were reduced compared with pre-
TAVI (rate ratio: 0.87 and 0.95 respectively; p< 0.01). 
However, all-cause, noncardiovascular (non-CV), and 
bleeding hospitalization rates and hospitalized days were 
increased (p< 0.01). Post-TAVI hospitalizations were 
reduced the most among those with LVEF<30%. There 
was only modest reduction in mean post-TAVI costs 
among all TAVI patients and 1-year survivors (rate ratio: 
0.95, p< 0.01; and 0.90; p< 0.01, respectively) 
(Vemulapalli S et al, J Am Coll Cardiol 2019;73:1135–46).  
 
EVEREST II @ 1 Year: MitraClip in Secondary Mitral 
Regurgitation (SMR) is Associated With Acceptable 
Safety, Reduction of MR Severity, Symptom 
Improvement, and Positive Ventricular Remodeling  
A total of 616 patients (482 high risk -HR, 134 non-
HR; mean age, 73.3±10.5 years; STS risk, 10.2±6.9%) 
with SMR received the MitraClip. At baseline, 80.5% of 
patients were in NYHA class III/IV. Major adverse events 
at 30 days included death (3.6%), stroke (2.3%), and renal 
failure (1.5%). At discharge, 88.8% had MR ≤2+. At 1 
year, there were 139 deaths, and freedom from mortality 
was 76.8%. The majority (84.7%) remained with MR ≤2+ 
and NYHA class I/II (83.0%). Survival at 1 year was 
74.1% in HR patients and 86.4% in non-HR patients 
(P=0.0175). At 1 year, both groups achieved comparable 
MR reduction (MR ≤2+, 84% vs 87%) and improvement 
in LV end-diastolic volume (−8.0 mL vs −12.7 mL), 
whereas NYHA class I/II was found in 80.1% vs 91.8% 
(P=0.008) of HR and non-HR patients, respectively. In HR 
patients, the annualized rate of heart failure 
hospitalizations decreased from 0.68 to 0.46 in the year 
before to the year after the procedure (P<0.0001) 
(Ailawadi G et al, Circulation 2019;139:37–47).  
 
Fingesture Study/Sudden Cardiac Death (SCD) in 
Women: Women More Likely to Experience 
Nonischemic SCD Than Men, With Primary 
Myocardial Fibrosis (PMF) a More Common Cause of 
Death Among Women Than in Men 
In a cohort of 5869 subjects with SCD, women were 
older when SCD occurred (70.1±13.1 vs 63.5±11.8 years, 
P<0.001), and ECGs of females were more likely to be 
normal than males (22.2% vs 15.3% in men, P<0.001), 
except for LVH which was more common in women (8.2% 
vs 4.9%, P=0.036). A normal ECG was even more 
common among nonischemic females with SCD (27.8% vs 
16.2% in men, P=0.009). The most frequently identified 
cause of death was ischemic heart disease in both sexes: 
71.7% vs 75.7%; P=0.005. In contrast, women were more 
likely to have nonischemic cause of SCD than men (28.3% 
vs 24.3%, P=0.005). The prevalence of primary 
myocardial fibrosis (PMF) was higher among women 
(5.2%) than in men (2.6%; P<0.001) (Haukilahti MAE et 
al, Circulation 2019;139:1012–21). 
 
Cardiac Amyloidosis (CA): In Patients With CA and 
Atrial Tachyarrhythmias Referred for Cardioversion, 
the Incidence of Atrial Appendage Thrombus is High 
Even Among Those who Have Received Anticoagulants  
CA patients (n=58, mean age 69 ± 9 years, 81% male) 
had a significantly higher cardioversion (DCCV) 
cancellation rate (28% vs. 7%; p< 0.001) compared with 
control patients, mainly due to intracardiac thrombus 
identified on transesophageal echocardiogram (TEE) (13 
of 16 or 81% vs 2 of 8 or 25%; p=0.02); 4 of 13 of the CA 
patients (31%) with intracardiac thrombus on TEE 
received adequate anticoagulation ≥3 weeks and another 2 
of 13 (15%) had arrhythmia duration <48 h. DCCV success 
rate (90% vs 94%; p=0.4) was not different. Procedural 
complications were more frequent in CA vs controls (6 of 
42 or 14% vs 2 of 106 or 2%; p=0.007); complications in 
CA included ventricular arrhythmias in 2 and severe 
bradyarrhythmias requiring pacemaker implantation in 2. 
The only complication in the control group was self-
limited bradyarrhythmias (El-Am EA et al et al, J Am Coll 
Cardiol 2019;73:589-97).  
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PRECISE-DAPT: The Risk of Bleeding Rather Than 
Ischemic Risk Should Determine the Duration of 
DAPT After PCI / Prolonging DAPT is Associated 
With a Reduction in Ischemic Events in Patients 
Undergoing Complex PCI Who are not at High 
Bleeding Risk (HBR), But Confers No Benefit in Those 
at HBR, Regardless of PCI Complexity  
Among 14,963 patients from 8 RCTs, 3,118 
underwent complex PCI and had a higher rate of ischemic, 
but not bleeding, events. Long-term DAPT in non-HBR 
patients reduced ischemic events in both complex and 
noncomplex PCI strata, but not among HBR patients, 
regardless of complex PCI features. The bleeding risk 
according to the TIMI scale was increased by long-term 
DAPT only in HBR patients, regardless of PCI complexity 
(Costa F et al, J Am Coll Cardiol 2019;73: 741-54).  
 
In an Animal Model, Serial Magnetic Resonance 
Imaging May Identify Early Stages of Anthracycline-
Induced Cardiotoxicity 
T2 mapping during treatment identifies intra-
cardiomyocyte edema generation as the earliest marker of 
anthracycline-induced cardiotoxicity, in the absence of T1 
mapping, extracellular volume, or LV motion defects. The 
occurrence of these changes at a reversible disease stage 
shows the clinical potential of this CMR marker for 
tailored anthracycline therapy (Galán-Arriola C et al, J Am 
Coll Cardiol 2019;73:779–91).  
 
Observational Data Suggest that NOACs May be 
Effective for Prevention of Thromboembolism in 
Patients With Mitral Stenosis and Atrial Fibrillation 
Among 2,230 AF patients with mitral stenosis (MS) 
(mean age 69.7 ± 10.5 years; 31% males) receiving oral 
anticoagulants (propensity score matched; n=1115 in each 
group), thromboembolic events occurred at a rate of 
2.22%/y in the NOAC group, and 4.19%/y in the warfarin 
group (adjusted hazard ratio-HR for NOAC: 0.28). 
Intracranial hemorrhage occurred in 0.49% of the NOAC 
group and 0.93% of the warfarin group (HR for DOAC: 
0.53) (Kim JY et al J Am Coll Cardiol 2019;73:1123-31).  
 
Large Noncortical or Cortical Infarcts (LNCCIs) in AF 
Patients Even in Anticoagulated Patients: Most Brain 
Infarcts Observed are Clinically Silent & Associated 
With Worse Cognitive Function, Raising the Question 
of MRI Screening in AF Patients 
Among 1,737 AF patients (age of 73 ± 8 years; 28% 
women, 90% taking oral anticoagulant agents), on MRI, 
LNCCIs were found in 387 patients (22%), small infarcts 
in 368 (21%), microbleeds in 372 (22%), and white matter 
lesions in 1715 (99%). Clinically silent infarcts among the 
1,390 patients without a history of stroke or TIA were 
found in 201 patients with LNCCIs (15%) and 245 patients 
with small infarcts (18%). The cognitive testing score was 
24.7 ± 3.3 in patients with and 25.8 ± 2.9 in those without 
LNCCIs (p< 0.001); the difference in score remained 
similar when only clinically silent LNCCIs were 
considered (24.9 ± 3.1 vs. 25.8 ± 2.9; p < 0.001). In a 
multivariable regression model including all vascular brain 
lesion parameters, LNCCI volume was the strongest 
predictor of reduced cognition (p< 0.001) (Conen D et al, 
J Am Coll Cardiol 2019;73:989-99).  
 
PRIME Study: Among Patients With Secondary 
Functional Mitral Regurgitation (MR), Sacubitril/ 
Valsartan Reduced MR to a Greater Extent Than did 
Valsartan  
Among 118 patients with heart failure with chronic 
functional MR secondary to left ventricular (LV) 
dysfunction randomly assigned to receive either sacubitril/ 
valsartan or valsartan, in addition to standard medical 
therapy for heart failure, the decrease in effective 
regurgitant orifice area was significantly greater in the 
sacubitril/valsartan group than in the valsartan group 
(P=0.032) in an intention-to-treat analysis including 117 
(99%) patients. Regurgitant volume was also significantly 
decreased in the sacubitril/valsartan group in comparison 
with the valsartan group (P=0.009). There was no 
significant difference in the change of blood pressure 
between the treatment groups, and 7 patients (12%) in the 
sacubitril/valsartan group and 9 (16%) in the valsartan 
group had ≥1 serious adverse events (P=0.54) (Kang D-H 
et al, Circulation 2019;139:1354–1365). 
 
Takotsubo Syndrome (TTS) Registry: Cardiogenic 
Shock Occurs in 10% and Portends a Worse Prognosis  
Of 2078 patients with TTS, 198 (9.5%) had cardiogenic 
shock (CS) (age 63.4±14.9 y vs 67.2±12.6 y, P<0.001 and 
more males 14.1% vs 9.3%, p=0.027, than those without 
CS). Patients with CS more often had physical triggers 
(66.7% vs 33%, p<0.001), and less often emotional 
triggers (10.6% vs 31.7%, p<0.001). Apical TTS occurred 
more often in patients with CS (80.3% vs 70.2%, p<0.001). 
AF (13.1% vs 5.7%, p<0.001) and lower LVEF (32.7 ± 
11.5% vs 41.6±11.3%, p<0.001) were detected more 
frequently in patients with CS. Patients with CS had a 
higher prevalence of major CV risk factors, e.g. diabetes 
(21% vs 14.8%, p=0.023) and smoking (27.4% vs 19.3%, 
p=0.010). Neurologic disorders were more prevalent in 
patients with CS (31.7% vs 23.4%, p=0.013). Apical TTS 
(odds ratio-OR, 1.68; p=0.007), physical stress (OR, 2.84; 
p<0.001), LVEF <45% (OR, 2.49; p<0.001), diabetes (OR, 
1.50; p=0.049), and AF on admission (OR, 2.03; p=0.007) 
were independently associated with CS. Patients with CS 
had a higher rate of in-hospital (23.5% vs 2.3%, p<0.001) 
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and 60-day (p<0.001) mortality. Patients with CS who 
received mechanical support (n=39) with intraaortic 
balloon (n=39), Impella (n=1), and/or ECMO (n=1), had a 
lower in-hospital mortality than those without mechanical 
support (12.8% vs 28.3%, p=0.046) (Di Vece D et al, 
Circulation 2019;139: 413-5). 
 
ECG Monitoring of Emergency Room (ER) Patients 
with Syncope: Serious Arrhythmia Was Often 
Identified Within the First 2h of ER Arrival for CSRS* 
Low-Risk Patients and Within 6h for CSRS Medium- 
and High-Risk Patients/ Outpatient Rhythm 
Monitoring for 15 Days for Selected Medium-Risk 
Patients and All High-Risk Patients Discharged from 
the Hospital Should be Considered  
Among 5581 patients (mean age, 53.4 years; 54.5% 
females; 11.6% hospitalized) presenting within 24 h of 
syncope in the emergency room (ER), 417 patients (7.5%) 
experienced serious outcomes, 207 of which (3.7%) were 
arrhythmic (161 arrhythmias, 30 cardiac device 
implantations, 16 unexplained deaths). Overall, 4123 
(73.9%) were classified as CSRS* low risk, 1062 (19%) 
medium risk, and 396 (7.1%) high risk. The CSRS 
accurately stratified subjects as low risk (0.4% risk for 30-
day arrhythmic outcome), medium risk (8.7% risk), and 
high risk (25.3% risk). One-half of arrhythmic outcomes 
were identified within 2 hours of ER arrival in low-risk 
patients and within 6 h in medium- and high-risk patients, 
and the residual risk after these cut points were 0.2% for 
low-risk, 5% for medium-risk, and 18.1% for high-risk 
patients. Overall, 91.7% of arrhythmic outcomes among 
medium- and high-risk patients, including all ventricular 
arrhythmias, were identified within 15 days. None of the 
low-risk patients experienced ventricular arrhythmia or 
unexplained death, whereas 0.9% of medium-risk patients 
and 6.3% of high-risk patients experienced them 
(P<0.0001) (Thiruganasambandamoorthy V et al, 
Circulation 2019;139:1396–1406).  
* Canadian Syncope Risk Score (CSRS) / The 9 predictors and 
their associated point values: ER diagnosis of vasovagal 
syncope, minus 2; predisposition to vasovagal symptoms, 
minus 1; abnormal QRS axis, QRS duration >130 ms, and 
history of heart disease, plus 1 each; any systolic BP recorded in 
the ER of <90 mm Hg or >180 mm Hg, elevated troponin level, 
QTc >480 ms, and ER diagnosis of cardiac syncope, plus 2 each 
/ Low risk: -3 to 0; medium: 1-3; high: 4-5; very high: 6-11.  
 
P2-CHA2DS2-VASc is a Better Prediction Tool for AF-
Related Ischemic Stroke than CHA2DS2-VASc: 
Abnormal P-Wave Axis-an ECG Correlate of Left 
Atrial Abnormality- Improves Stroke Prediction in AF  
Among 2229 participants from the ARIC study and 700 
participants from MESA with incident AF who were not 
on anticoagulants within 1 year of AF diagnosis, abnormal 
P-wave axis was associated with increased ischemic stroke 
risk (hazard ratio, 1.84) independent of CHA2DS2-VASc 
variables, and resulted in meaningful improvement in 
stroke prediction. The β estimate was approximately twice 
that of the CHA2DS2-VASc variables, and thus abnormal 
P-wave axis was assigned 2 points to create the P2-
CHA2DS2-VASc score. This improved the C-statistic from 
0.60 to 0.67 in ARIC and 0.68 to 0.75 in MESA (validation 
cohort). In ARIC and MESA, the categorical net 
reclassification improvements were 0.25 and 0.51, 
respectively, and the relative integrated discrimination 
improvements were 1.19 and 0.82, respectively 
(Maheshwari A et al, Circulation 2019;139:180–191).  
 
Noninvasive Electrophysiology-Guided Cardiac 
Radioablation: Reduced Ventricular Arrhythmia 
Burden With Modest Short-Term Risks/Reduced Anti-
arrhythmic Drug Use/Improved Quality of Life  
Among 19 patients submitted to radioablation (17 VT, 
2 for PVC-cardiomyopathy; median ablation time 15.3 
min), over 3 months, 2/19 patients (10.5%) had a treatment 
-related adverse event. The median number of VT episodes 
was reduced from 119 to 3 (p<0.001). Reduction was 
observed for both ICD shocks and anti-tachycardia pacing. 
VT episodes or PVC burden were reduced in 17/18 
evaluable patients (94%). The frequency of VT episodes 
or PVC burden was reduced by 75% in 89% of patients. 
Survival was 89% at 6 and 72% at 12 months. Use of dual 
antiarrhythmic drugs decreased from 59% to 12% 
(p=0.008). Quality of life improved at 6 months (Robinson 
CG et al, Circulation 2019;139:313–21). 
 
Meta-Analysis: Catheter Ablation of AF in HF Patients 
was Superior to Drug Therapy in Improving Mortality, 
HF Hospitalizations, LVEF, 6-Minute Walk Test 
Distance, Vo2max, and Quality of Life, with no 
Significant Increase in Adverse Events. 
In 6 RCTs involving 775 HF patients, compared with 
drug therapy, AF ablation reduced all-cause mortality 
(9.0% vs 17.6%; risk ratio-RR, 0.52) and HF 
hospitalizations (16.4% vs 27.6%; RR, 0.60). Ablation 
improved LVEF (mean difference, 6.95%), 6-minute walk 
test distance (mean difference, 20.93 m), peak oxygen 
consumption (Vo2max) (mean difference, 3.17 mL/kg per 
minute), and quality of life (mean difference in Minnesota 
Living with Heart Failure Questionnaire score, −9.02 
points). Serious adverse events were more common in the 
ablation groups, although differences between the ablation 
and drug therapy groups were not statistically significant 
(7.2% vs 3.8%; RR, 1.68) (Turagam MK et al, Ann Intern 
Med 2019;170:41-50).  
 
40 
 
 
IABP-SHOCK II: IABP Had no Effect on All-Cause 
Mortality at 6-Year Follow-Up / Mortality is Still Very 
High, With 2/3 Dying Despite Revascularization  
Follow-up was performed 6.2 years after initial 
randomization and was completed for 591 of 600 patients 
(98.5%). Mortality was not different between the IABP 
and the control group (66.3% vs 67%; relative risk, 0.99; 
P=0.98). There were also no differences in recurrent MI, 
stroke, repeat revascularization, or rehospitalization for 
cardiac reasons (all P>0.05). Survivors’ quality of life and 
the NYHA class did not differ between groups (Thiele H 
et al, Circulation 2019;139:395–403).  
 
APOLLO Study: Patisiran May Halt or Reverse the 
Progression of Cardiac Manifestations of Hereditary 
Transthyretin-Mediated Amyloidosis (hATTR)  
Patients with hATTR were randomized 2:1 to IV 0.3 
mg/kg patisiran or placebo every 3 weeks for 18 months. 
In the cardiac subpopulation (n=126), patisiran reduced 
mean LV (p=0.017), septal, posterior, and relative wall 
thickness at month 18. Patisiran also led to increased end-
diastolic volume (8.3±3.9 mL, p=0.036), decreased global 
longitudinal strain (–1.4±0.6%, p=0.015), and increased 
cardiac output (0.38±0.19 L/min, p=0.044) compared with 
placebo at month 18. It lowered NT-proBNP at 9 and 18 
months (p<0.001). At a median of 18.7 months, patisiran 
reduced the rates of cardiac hospitalizations and all-cause 
death (10.1 vs 18.7 per 100 patient-years; hazard ratio, 
0.54) (Solomon SD et al, Circulation 2019;139:431–43)  
 
Influenza Vaccination in Heart Failure (HF) Patients: 
Reduces Risk of All-Cause and Cardiovascular (CV) 
Death / Frequent Vaccination and Vaccination Earlier 
in the Year Confers Larger Reductions  
Among HF patients (n=134,048) over a median of 3.7 
years, with vaccination coverage ranging from 16% to 
54%, after adjustment for inclusion date, comorbidities, 
medications, income, and education level, receiving ≥1 
vaccinations conferred an 18% reduced risk of death (all-
cause: hazard ratio-HR, 0.82; p<0.001; CV causes: HR, 
0.82; p<0.001). Annual vaccination, vaccination early in 
the year (September to October), and greater cumulative 
number of vaccinations were associated with larger 
reductions in the risk of death compared with intermittent 
vaccination (Modin D et al, Circulation 2019; 139:575-86) 
 
REDUCE-IT: In Patients With High Triglycerides 
Despite Use of Statins, the Risk of Ischemic Events, 
Including CV Death, was Lower in Those Who 
Received 2 g of Icosapent Ethyl bid Than Those Who 
Received Placebo 
A total of 8179 patients with established CV disease or 
diabetes and other risk factors, who had been on statin 
therapy and who had a fasting triglyceride level of 135-499 
mg/dl and a LDL cholesterol level of 41-100 mg/dl were 
randomly assigned to receive 2 g of icosapent ethyl bid 
(total daily dose, 4 g) or placebo (70.7% for secondary 
prevention of CV events) and were followed for a median 
of 4.9 years. A primary end-point event (composite of CV 
death, MI, stroke, coronary revascularization, or unstable 
angina) occurred in 17.2% of the patients in the icosapent 
ethyl group, as compared with 22% in the placebo group 
(hazard ratio-HR, 0.75; P<0.001); the corresponding rates 
of the key secondary end point (composite of CV death, 
MI, or stroke) were 11.2% and 14.8% (HR, 0.74; P<0.001). 
The rates of additional ischemic end points were lower in 
the icosapent ethyl group than in the placebo group, 
including the rate of CV death (4.3% vs 5.2%; HR, 0.80; 
P=0.03). A larger percentage of patients in the icosapent 
ethyl group than in the placebo group were hospitalized for 
atrial fibrillation or flutter (3.1% vs 2.1%, P=0.004). 
Serious bleeding events occurred in 2.7% of the patients in 
the icosapent ethyl group and in 2.1% in the placebo group 
(P=0.06) (Bhatt DL et al, N Engl J Med 2019; 380:11-22). 
 
CLEAR Harmony Trial: Over 52 Weeks, Bempedoic 
Acid Added to Maximally Tolerated Statin Therapy 
did not Lead to a Higher Incidence of Overall Adverse 
Events Than Placebo and Led to Lower LDL Levels  
Among 2230 patients with atherosclerotic 
cardiovascular disease, heterozygous familial hyperchole-
sterolemia, or both on maximally tolerated statin therapy 
and LDL>70 mg/dl (mean 103.2±29.4 mg/dl), of whom 
1488 were randomized to bempedoic acid and 742 to 
placebo, the incidence of adverse events (78.5% in the 
bempedoic acid group and 78.7% in the placebo group) 
and serious adverse events (14.5% and 14%, respectively) 
did not differ substantially between the two groups during 
the intervention period, but the incidence of adverse events 
leading to discontinuation of the regimen was higher in the 
bempedoic acid group than in the placebo group (10.9% vs 
7.1%), as was the incidence of gout (1.2% vs 0.3%). At 
week 12, bempedoic acid reduced the mean LDL 
cholesterol level by 19.2 mg/dl, representing a change of 
−16.5% from baseline (difference vs. placebo in change 
from baseline, –18.1 percentage points; P<0.001). Safety 
and efficacy findings were consistent, regardless of the 
intensity of background statin therapy (Ray KK et al, N 
Engl J Med 2019;380:1022-32). 
 
ODYSSEY Outcomes: The Price of Alirocumab Would 
Have to be Reduced Drastically to be Cost-Effective  
Compared with a statin alone, the addition of 
ezetimibe cost $81,000 per QALY. Compared with a statin 
alone, the addition of alirocumab cost $308,000 per 
QALY. Compared with the combination of statin and 
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ezetimibe, replacing ezetimibe with alirocumab cost 
$997,000 per QALY. The price of alirocumab would have 
to decrease from its original cost of $14,560 to $1974 
annually to be cost-effective relative to ezetimibe (Kazi DS 
et al, Ann Intern Med 2019;170:221-229). 
 
FOURIER Trial: Higher Lipoprotein(a) - Lp(a) Levels 
are Associated with Increased Risk of CV Events in 
Patients with CV Disease Irrespective of LDL 
Cholesterol / Evolocumab Reduced Lp(a) Levels, and 
Patients With Higher Baseline Lp(a) Experienced 
Greater Absolute Reductions in Lp(a) and Tended to 
Derive Greater Benefit from PCSK9 Inhibition 
The median baseline Lp(a) concentration was 37 
nmol/L. In the placebo arm, patients with baseline Lp(a) in 
the highest quartile had a higher risk of CAD death, MI, or 
urgent revascularization (adjusted hazard ratio quartile 4: 
quartile 1, 1.22) independent of LDL cholesterol. At 48 
weeks, evolocumab reduced Lp(a) by a median of 26.9%. 
The percent change in Lp(a) and LDL cholesterol at 48 
weeks in patients taking evolocumab was moderately 
positively correlated (r=0.37; p<0.001). Evolocumab 
reduced the risk of CAD death, MI, or urgent 
revascularization by 23% (hazard ratio-HR, 0.77) in 
patients with a baseline Lp(a) >median, and by 7% (HR, 
0.93; p interaction=0.07) in those ≤median. Coupled with 
the higher baseline risk, the absolute risk reductions, and 
number needed to treat over 3 years were 2.49% and 40 vs 
0.95% and 105, respectively (O’Donoghue ML et al, 
Circulation 2019;139:1483–92).  
 
VITAL Trial: Supplementation With Vitamin D or ω-
3 Fatty Acids did not Result in a Lower Incidence of 
Cancer or Cardiovascular Events Than Placebo 
Among 25,871 individuals (men>50 years/ women 
>55 years) randomized to vitamin D3 (cholecalciferol) 
(2000 IU/d) and ω-3 fatty acids (1 g/d), supplementation 
with vitamin D or ω-3 fatty acids was not associated with 
a lower risk of either of the primary end points (cancer of 
any type and major cardiovascular - CV events) during a 
median follow-up of 5.3 years. No excess risks of 
hypercalcemia or other adverse events were identified with 
vitamin D and no excess risks of bleeding or other serious 
adverse events were observed with ω-3 free fatty acids. 
(Manson JF et al, N Engl J Med 2019; 380:33-44 & 23-32).  
 
CARMELINA: In Patients With Type 2 Diabetes and 
Cardiovascular (CV) Disease and/or Kidney Disease, 
Linagliptin did not Affect the Risk of Heart Failure 
(HF) Hospitalization (hHF) or Other Selected HF-
Related Outcomes   
Among 6979 participants (mean age, 65.9 years; 
eGFR, 55 mL/min per 1.73m2; hemoglobin A1c, 8%; 
62.9% men), including 1873 (26.8%) with a history of HF 
at baseline, over a median of 2.2 years, linagliptin vs 
placebo did not affect the incidence of hHF (6% vs 6.5%, 
respectively; hazard ratio -HR, 0.90), the composite of CV 
death/hHF (HR, 0.94), or risk for recurrent hHF events 
(326 vs 359 events, respectively; rate ratio, 0.94) (Sharma 
A et al, Circulation 2018;138:1666–1676).  
 
DECLARE–TIMI 58: In Patients With Type 2 
Diabetes Who Had or Were at Risk for Atherosclerotic 
Cardiovascular (CV) Disease (CVD), Treatment With 
Dapagliflozin did not Change MACE Rate vs Placebo 
But Did Result in a Lower Rate of CV Death or Heart 
Failure (HF) Hospitalization, Reflecting a Lower Rate 
of HF Hospitalization  
Among 17,160 patients, including 10,186 without 
atherosclerotic CVD, followed for a median of 4.2 years, 
dapagliflozin met the prespecified criterion for 
noninferiority to placebo with respect to MACE (upper 
boundary of the 95% confidence interval, <1.3; P<0.001 
for noninferiority). In the two primary efficacy analyses, 
dapagliflozin did not result in a lower rate of MACE (8.8% 
vs 9.4%; hazard ratio-HR, 0.93; P=0.17) but did result in a 
lower rate of CV death or HF hospitalization (4.9% vs. 
5.8%; HR, 0.83; P=0.005), which reflected a lower rate of 
HF hospitalization (HR, 0.73); there was no between-
group difference in CV death (HR, 0.98). A renal event 
occurred in 4.3% in the dapagliflozin group and in 5.6% in 
the placebo group (HR, 0.76), and death from any cause 
occurred in 6.2% and 6.6%, respectively (HR, 0.93). 
Diabetic ketoacidosis was more common with 
dapagliflozin than with placebo (0.3% vs 0.1%, P=0.02), 
as was the rate of genital infections that led to 
discontinuation of the regimen or that were considered to 
be serious adverse events (0.9% vs 0.1%, P<0.001) 
(Wiviott SD et al, N Engl J Med 2019; 380:347-357).  
 
EMPA-REG OUTCOME Trial: Empagliflozin 
Reduced Mortality and Hospitalization for Heart 
Failure Across the Spectrum of Cardiovascular Risk  
Of 7020 patients who received empagliflozin, 65% had 
a prior MI or stroke, 12% were at low, 40% at intermediate, 
30% at high, and 18% were at highest cardiovascular 
(TIMI) risk. In the placebo group, 3-point MACE occurred 
during the trial in 7.3%, 9.4%, 12.6%, and 20.6% of 
patients at low, intermediate, high, and highest estimated 
baseline risk, respectively. Relative reductions in risk of 
CV death, all-cause mortality, 3-point MACE and 
hospitalization for heart failure with empagliflozin vs 
placebo were consistent in patients with and without prior 
MI and/or stroke and across subgroups by TIMI Risk Score 
at baseline (P>0.05) (Fitchett D et al, Circulation 2019; 
139:1384–1395).  
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Meta-Analysis: SGLT2 Inhibitors (SGLT2i) Have 
Moderate Benefits on Major Adverse CV Events 
(MACE) Confined to Patients With Established 
Atherosclerotic CV Disease (CVD) / They Also Have 
Robust Benefits on Reducing Hospitalization for Heart 
Failure (HF) and Progression of Renal Disease 
Regardless of Existing CVD or a History of HF 
Data from 3 trials (EMPA-REG, CANVAS, and 
DECLARE-TIMI 58) and 34,322 patients (60.2% with 
established atherosclerotic CVD), with 3342 MACE, 2028 
CV deaths or HF hospitalization, and 766 renal composite 
outcomes, indicated that SGLT2i reduced MACE by 11% 
(HR 0.89, p=0.0014), with benefit only seen in patients 
with CVD (HR 0.86) and not in those without (HR 1.00, p 
for interaction=0·0501). SGLT2i reduced the risk of CV 
death or HF hospitalization by 23% (HR 0.77, p<0.0001), 
with a similar benefit in patients with and without CVD 
and with and without a history of HF. SGLT2i reduced the 
risk of progression of renal disease by 45% (HR 0.55, 
p<0.0001), with a similar benefit in those with and without 
CVD. The magnitude of benefit of SGLT2i varied with 
baseline renal function, with greater reductions in HF 
hospitalizetions (p for interaction=0.0073) and lesser 
reductions in progression of renal disease (p for interaction 
= 0.0258) in patients with more severe kidney disease at 
baseline (Zelniker TA et al, Lancet 2019;393:31-39.  
 
CASSINI Trial: In High-Risk Ambulatory Patients 
With Cancer, Rivaroxaban Did Not Result in a Lower 
Incidence of VTE or Death Due to VTE Over 6-Months 
/ However, During the Pre-specified Intervention 
Period, Rivaroxaban Led to a Lower Incidence of Such 
Events, With a Low Incidence of Major Bleeding  
Among 841 high-risk ambulatory patients with cancer 
(Khorana score of ≥2), randomized to rivaroxaban (10 mg) 
or placebo daily for up to 3 months, the primary end point 
(composite of DVT in a lower limb, pulmonary embolism, 
symptomatic DVT in an upper limb or distal DVT in a 
lower limb, and death from VTE) occurred in 6% 
(rivaroxaban) vs 8.8% (placebo) (hazard ratio-HR, 0.66; 
P=0.10). In the prespecified intervention-period (first 
receipt of trial agent to last dose plus 2 days) analysis, the 
primary end point occurred in 2.6% vs 6.4% (HR, 0.40). 
Major bleeding occurred in 2% vs 1% (HR, 1.96) (Khorana 
AA et al, N Engl J Med 2019; 380:720-728).  
 
AVERT Trial: Apixaban Conferred a Lower Rate of 
Venous Thromboembolism Than Did Placebo Among 
Intermediate-To-High-Risk Ambulatory Patients With 
Cancer Who Were Starting Chemotherapy, Albeit with 
a Higher Rate of Major Bleeding Episodes  
An RCT assessed the efficacy and safety of apixaban 
(2.5 mg bid) for thromboprophylaxis in ambulatory 
patients with cancer who were at intermediate-to-high risk 
for venous thromboembolism (VTE) (Khorana score, ≥2) 
and were initiating chemotherapy. Of the 574 patients who 
underwent randomization, 563 were included in the 
modified intention-to-treat analysis. Over 6 months, VTE 
occurred in 4.2% in the apixaban group and in 10.2% in 
the placebo group (hazard ratio-HR, 0.41; P<0.001). In the 
modified intention-to-treat analysis, major bleeding 
occurred in 3.5% vs 1.8% (HR, 2.00; P=0.046). During the 
treatment period, major bleeding occurred in 2.1 vs 1.1% 
(HR, 1.89) (Carrier M et al, New Engl J Med 2019; 
380:711-719). 
 
PIONEER-HF: Among Patients With Heart Failure 
(HF) With Reduced Ejection Fraction (HFrEF) Who 
Were Hospitalized for Acute Decompensated HF, 
Initiation of Sacubitril–Valsartan Led to a Greater 
Reduction in NT-ProBNP Than Enalapril with Similar 
Rates of Worsening Renal Function, Hyperkalemia, 
Symptomatic Hypotension, and Angioedema  
Among 881 HFrEF patients randomized to sacubitril–
valsartan (target dose 97/103 mg, n=440) or enalapril 
(target dose 10 mg bid, n=441), the time-averaged 
reduction in the NT-proBNP was greater in the sacubitril–
valsartan group ; the ratio of the geometric mean of values 
obtained at weeks 4 and 8 to the baseline value was 0.53 
vs 0.75 (percent change, −46.7% vs −25.3%; ratio of 
change, 0.71; P<0.001). The greater reduction in the NT-
proBNP concentration with sacubitril–valsartan was 
evident as early as week 1 (ratio of change, 0.76). The rates 
of worsening renal function, hyperkalemia, symptomatic 
hypotension, and angioedema did not differ between the 
two groups (Velazquez EJ et al, N Engl J Med 2019; 
380:539-548).  
 
POET: In Patients With Left-Sided Endocarditis Who 
Were in Stable Condition, Changing to Oral Antibiotic 
Treatment Was Noninferior to Continued Intravenous 
(IV) Antibiotic Treatment  
Among 400 adults in stable condition who had left-
sided endocarditis caused by streptococcus, Enterococcus 
faecalis, Staphylococcus aureus, or coagulase-negative 
staphylococci and who were being treated with IV 
antibiotics for at least 10 days and then randomized to 
continue IV treatment (199 patients) or to switch to oral 
antibiotic treatment (201 patients), who finally completed 
treatment after a median of 19 days (IV group) vs 17 days 
(oral group), the primary composite outcome (all-cause 
mortality, unplanned cardiac surgery, embolic events, or 
relapse of bacteremia) occurred in 24 patients (12.1%) in 
the intravenous group and in 18 (9%) in the oral group 
(between-group difference, 3.1 percentage points; 
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P=0.40), which met noninferiority criteria (Iversen K et al, 
N Engl J Med 2019; 380:415-424).  
 
TRED-HF: Patients Who Have Recovered from 
Dilated Cardiomyopathy (DCM) Will Relapse 
Following Treatment Withdrawal / Until Robust 
Predictors of Relapse are Defined, Treatment Should 
Continue Indefinitely  
Of 51 patients with DCM, 25 were randomly assigned 
to the treatment withdrawal group and 26 to continue 
treatment. Over the first 6 months, 11 (44%) patients had 
a relapse compared with none of those assigned to continue 
treatment (Kaplan-Meier estimate of event rate 45.7%; 
p=0.0001). After 6 months, 25 (96%) of 26 patients 
assigned initially to continue treatment attempted 
withdrawal. During the following 6 months, 9 patients had 
a relapse (Kaplan-Meier estimate of event rate 36%). No 
deaths were reported in either group (Halliday BP, Lancet 
2019;393(10166):61-73). 
 
Meta-Analysis: Statin Therapy Produces Significant 
Reductions in Major Vascular Events Irrespective of 
Age, But There is Less Direct Evidence of Benefit 
Among Patients Older Than 75 Years Who Do Not 
Already Have Evidence of Occlusive Vascular Disease  
 
A total of 14,483 (8%) of 186,854 participants in 28 
statin trials were older than 75 years. Over a median of 4.9 
years, statin therapy produced a 21% proportional 
reduction in major vascular events per 1.0 mmol/L 
reduction in LDL cholesterol. A significant reduction was 
observed in major vascular events in all age groups. 
Proportional reductions in major vascular events 
diminished slightly, albeit not statistically, with age. 
Overall, statin or more intensive therapy yielded a 24% 
proportional reduction in major coronary events per 1.0 
mmol/L reduction in LDL cholesterol, and with increasing 
age, a trend was observed towards smaller proportional 
risk reductions. There was a 25% proportional reduction in 
the risk of coronary revascularization procedures with 
statin therapy per 1.0 mmol/L lower LDL cholesterol, 
similar across age groups. There were similar proportional 
reductions in stroke of any type across age groups. There 
were smaller proportional risk reductions with increasing 
age. The proportional reduction in major vascular events 
was similar, irrespective of age, among patients with pre-
existing vascular disease, but appeared smaller among 
older than among younger individuals not known to have 
vascular disease. A 12% proportional reduction was 
observed in vascular mortality, with a trend towards 
smaller proportional reductions with older age, which did 
not persist after exclusion of the heart failure or dialysis 
trials. Statin therapy had no effect at any age on non-
vascular mortality, cancer death, or cancer incidence 
(Cholesterol Treatment Trialists, Lancet 2019;393:407-
415).  
 
Predicting ~1% Median 5-Year Bleeding Risk to Guide 
Aspirin Use for the Primary Prevention of 
Cardiovascular Disease (CVD) 
 
In a study cohort comprising 385,191 persons aged 30-
79 years whose CVD risk was assessed, during 1,619,846 
person-years of follow-up, 4442 persons had major 
bleeding events (of which 7% were fatal). The main 
models predicted a median 5-year bleeding risk of 1% in 
women and 1.1% in men. Plots of predicted-against-
observed event rates showed good calibration throughout 
the risk range (Selak V et al, Ann Intern Med 
2019;170:357-368).  
  
Important Review and Other Articles  
  
● Electric car EMI in patients with CIEDs (Turagam MK et al, 
J Am Coll Cardiol 2019;73:210-3) 
 
Use of medication for cardiovascular disease during pregnancy 
(Halpern DG et al, J Am Coll Cardiol 2019;73:457-76) 
 
● 2018 AATS/ACC/SCAI/STS Expert Consensus Systems of 
Care Document: Operator and Institutional Recommendations 
and Requirements for TAVI (Bavaria JE et al, J Am Coll Cardiol 
2019;73:340-74) 
 
● AF and cognitive function (Diener H-C et al, J Am Coll 
Cardiol 2019;73:612-19) 
 
● HFpEF and diabetes (McHugh K et al, J Am Coll Cardiol 
2019;73:602-11) 
 
● Lyme carditis (Yeung C & Baranchuk A, J Am Coll Cardiol 
2019;73:717-26)  
 
● Non-alcoholic fatty liver disease and the heart (Stahl EP et al, 
J Am Coll Cardiol 2019;73:948-63)  
 
● Anticoagulation in cancer patients (Mosarla RC et al, J Am 
Coll Cardiol 2019;73:1336-49) 
 
● Postural orthostatic tachycardia syndrome (POTS) (Bryarly M 
et al, J Am Coll Cardiol 2019;73:1207-28) 
 
● Autonomic nervous system dysfunction (Goldberger JJ et al, 
J Am Coll Cardiol 2019;73:1189-206) 
 
● Cardio-Oncology: vascular & metabolic perspectives 
(Campia U et al, Circulation 2019;139:e579–e602) 
 
● Mitochondrial dysfunction in HFpEF (Kumar AA et al, 
Circulation 2019;139:1435–1450) 
 
● Acute infection and MI (Musher DM et al, N Engl J Med 
2019; 380:171-176) 
